Neuroone Medical Technologies (NMTC) Liabilities and Shareholders Equity (2010 - 2026)

Neuroone Medical Technologies has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $7.6 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 69.83% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (up 77.79% YoY) and the FY2025 annual result came in at $10.8 million, up 100.85% from the prior year.
• Liabilities and Shareholders Equity retreated to $7.6 million in Q1 2026, from $8.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $14.1 million in Q1 2022 and bottomed at $4.5 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $7.6 million (2026), against an average of $8.2 million.
• Year-over-year, Liabilities and Shareholders Equity tumbled 50.24% in 2023 and surged 120.24% in 2025.
• Neuroone Medical Technologies' Liabilities and Shareholders Equity stood at $9.7 million in 2022, then slumped by 39.73% to $5.8 million in 2023, then increased by 11.54% to $6.5 million in 2024, then jumped by 32.08% to $8.6 million in 2025, then declined by 11.76% to $7.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.6 million, $8.6 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.